Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atezolizumab plus neoadjuvant ddAC followed by paclitaxel, trastuzumab, and pertuzumab in early HER2-positive breast cancer
2018-001881-40Phase 3Completed
- Sponsor
- Roche
- Start
- Sep 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in breast cancer comparing Atezolizumab + ddAC-PacHP with Placebo + ddAC-PacHP (2 arms). Primary endpoints: Pathological complete response in PD-L1-positive population and Pathological complete response in ITT population. Started Sep 2018; status: completed.
02
Drugs
atezolizumab
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2018-001881-40.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-001881-40.